319 related articles for article (PubMed ID: 12739069)
21. Requirement for efficient interactions between CD4 and MHC class II molecules for survival of resting CD4+ T lymphocytes in vivo and for activation-induced cell death.
Maroto R; Shen X; König R
J Immunol; 1999 May; 162(10):5973-80. PubMed ID: 10229835
[TBL] [Abstract][Full Text] [Related]
22. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells.
Desbarats J; Duke RC; Newell MK
Nat Med; 1998 Dec; 4(12):1377-82. PubMed ID: 9846574
[TBL] [Abstract][Full Text] [Related]
23. Cutting edge: CD4+ T cells kill CD8+ T cells via Fas/Fas ligand-mediated apoptosis.
Piazza C; Gilardini Montani MS; Moretti S; Cundari E; Piccolella E
J Immunol; 1997 Feb; 158(4):1503-6. PubMed ID: 9029083
[TBL] [Abstract][Full Text] [Related]
24. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
[TBL] [Abstract][Full Text] [Related]
25. Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation.
Prabhu Das MR; Zamvil SS; Borriello F; Weiner HL; Sharpe AH; Kuchroo VK
Eur J Immunol; 1995 Jan; 25(1):207-11. PubMed ID: 7531145
[TBL] [Abstract][Full Text] [Related]
26. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
Martin BK; Frelinger JG; Ting JP
J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
[TBL] [Abstract][Full Text] [Related]
27. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
28. The role of the antigen-presenting cell in Fas-mediated direct and bystander killing: potential in vivo function of Fas in experimental allergic encephalomyelitis.
Thilenius AR; Sabelko-Downes KA; Russell JH
J Immunol; 1999 Jan; 162(2):643-50. PubMed ID: 9916681
[TBL] [Abstract][Full Text] [Related]
29. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon.
Tsukada N; Aoki S; Maruyama S; Kishi K; Takahashi M; Aizawa Y
J Exp Clin Cancer Res; 1997 Jun; 16(2):171-6. PubMed ID: 9261743
[TBL] [Abstract][Full Text] [Related]
30. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma.
Tatsumi T; Takehara T; Katayama K; Mochizuki K; Yamamoto M; Kanto T; Sasaki Y; Kasahara A; Hayashi N
Hepatology; 1997 May; 25(5):1108-14. PubMed ID: 9141426
[TBL] [Abstract][Full Text] [Related]
31. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
32. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
Ragnarsson GB; Mikaelsdottir EK; Vidarsson H; Jónasson JG; Olafsdóttir K; Kristjánsdóttir K; Kjartansson J; Ogmundsdóttir HM; Rafnar T
Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571
[TBL] [Abstract][Full Text] [Related]
33. Rapid induction of CD95 ligand and CD4+ T cell-mediated apoptosis by CD137 (4-1BB) costimulation.
Ebata T; Mogi S; Hata Y; Fujimoto JI; Yagita H; Okumura K; Azuma M
Eur J Immunol; 2001 May; 31(5):1410-6. PubMed ID: 11465097
[TBL] [Abstract][Full Text] [Related]
34. A triad of costimulatory molecules synergize to amplify T-cell activation.
Hodge JW; Sabzevari H; Yafal AG; Gritz L; Lorenz MG; Schlom J
Cancer Res; 1999 Nov; 59(22):5800-7. PubMed ID: 10582702
[TBL] [Abstract][Full Text] [Related]
35. Post-thymic selection of peripheral CD4+ T-lymphocytes on class II major histocompatibility antigen-bearing cells.
Shen X; König R
Cell Mol Biol (Noisy-le-grand); 2001 Feb; 47(1):87-96. PubMed ID: 11292263
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast.
Yakirevich E; Maroun L; Cohen O; Izhak OB; Rennert G; Resnick MB
J Pathol; 2000 Oct; 192(2):166-73. PubMed ID: 11004692
[TBL] [Abstract][Full Text] [Related]
37. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation.
Esser MT; Graham DR; Coren LV; Trubey CM; Bess JW; Arthur LO; Ott DE; Lifson JD
J Virol; 2001 Jul; 75(13):6173-82. PubMed ID: 11390619
[TBL] [Abstract][Full Text] [Related]
38. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
[TBL] [Abstract][Full Text] [Related]
39. Immunogene therapy against mouse leukemia using B7 molecules.
Takahashi T; Hirano N; Takahashi T; Chiba S; Yazaki Y; Hirai H
Cancer Gene Ther; 2000 Jan; 7(1):144-50. PubMed ID: 10678367
[TBL] [Abstract][Full Text] [Related]
40. B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation.
Brown R; Murray A; Pope B; Sze D; Gibson J; Ho PJ; Joshua D
Leuk Lymphoma; 2004 Feb; 45(2):363-71. PubMed ID: 15101725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
